Appendix 3G — Performance Rights and Performance Options

Aug 6, 2020
Posted in: Investor updates

Home » Appendix 3G — Performance Rights and Performance Options

Appendix 3G — Performance Rights and Performance Options

Aug 6, 2020
Posted in: Investor updates

Imagion Biosystems has announced Appendix 3G — FY20 Performance Rights and Performance Options.

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent

January 31, 2026

Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has

Quarterly Activities Report and Appendix 4C – December 2025

January 28, 2026

Key Highlights: Manufacturing and Testing of MagSense® HER2 Imaging Agent Completed, Paving Way for IND Submission Q1 2026 Wayne State University Collaboration for MRI Optimization

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Appendix 3G — Performance Rights and Performance Options

Appendix 3G — Performance Rights and Performance Options

Related Articles

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent

Quarterly Activities Report and Appendix 4C – December 2025

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list